Response to Cioffi. by Eyal, Nir et al.
Dr Cioffi rails against our comparison of human challenge studies to organ donation, but the risk of 
donor death from live kidney donation is about 3 per 10,0001 which is similar to a recent estimate of 
that following SARS-CoV-2 infection among people in their twenties2. Lowering the age cap would 
reduce the risk compared to the wider age range we suggested in our paper. Furthermore, the risk to 
challenge volunteers may be lower if recruitment is restricted to those with no underlying health 
conditions. While it is likely that some small risk of severe outcomes will remain, in the absence of 
effective treatments, in the future it may be possible to reduce risk still further as knowledge is 
developed on any individual characteristics that predispose to severe outcomes.  
 
One of our main arguments justifying human challenge trials of SARS-Cov-2 vaccines has been 
overlooked. Participant selection from high-transmission areas would translate into selecting from those 
at high background risk of natural SARS-Cov-2 infection. Moreover, in the likely over-burdened care 
system of a high-transmission area, access to critical care might be suboptimal, but in a challenge study 
it could and should be guaranteed. Thus, participation in a challenge study may not materially worsen 
volunteers’ risk of small risk of severe disease and death.  
 
Dr Cioffi questions the quality of consent to challenge trial participation. We agree that this aspect 
would need very careful attention, which may include psychiatric evaluation, but we believe that a 
rational person could participate in a challenge study (or donate a kidney) motivated by altruism.  
 
Dr Cioffi’s overarching allegation, that we assume a simplistic utilitarian ethic that sacrifices individual 
rights for collective goals, overlooks our conclusion, that human challenge trials “do not violate 
participants’ individual rights on the altar of emergency response, but heed both individual rights and 
the global public health emergency.” It was to show how challenge trials are consonant with 
participants’ rights that we belabored the balance of risks and benefits to the participants, as well as 
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